TranS1 update – some good news and some bad news
Good news and bad news for for TranS1:
+ New 510(k) clearance for its next-generation AxiaLIF 1L
+ Released two clinical papers highlighting the efficacy and safety of the AxiaLIF spinal fusion procedure have been approved for publication in leading spine peer-reviewed journals.
– Lowered Q1 guidance by $1.2M due to “general spine market conditions and ongoing AxiaLIF physician reimbursement pressure.”